首页> Frontiers in pharmacology> The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study.

The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study.

导出 LinkOut

翻译打印收藏纠错

第一作者： Sara,Galimberti

第一单位： Section of Hematology, Department of Clinical and Experimental Medicine, University of PisaPisa, Italy.

作者： Sara,Galimberti ^[1] ; Elena,Ciabatti ^[1] ; Giacomo,Ercolano ^[1] ; Susanna,Grassi ^[2] ; Francesca,Guerrini ^[1] ; Nadia,Cecconi ^[1] ; Martina,Rousseau ^[1] ; Giulia,Cervetti ^[1] ; Francesco,Mazziotta ^[1] ; Lorenzo,Iovino ^[1] ; Franca,Falzetti ^[3] ; Flavio,Falcinelli ^[3] ; Alberto,Bosi ^[4] ; Luigi,Rigacci ^[4] ; Sofia,Kovalchuk ^[4] ; Daniele,Vallisa ^[5] ; Lucia,Macchia ^[1] ; Eugenio,Ciancia ^[6] ; Mario,Petrini ^[1]

作者单位： Section of Hematology, Department of Clinical and Experimental Medicine, University of PisaPisa, Italy. ^[1] Section of Hematology, Department of Clinical and Experimental Medicine, University of PisaPisa, Italy.;Doctoral School of Genetics, Oncology and Clinical Medicine (GeNOMEC), University of SienaSiena, Italy. ^[2] Department of Hematology, University of PerugiaPerugia, Italy. ^[3] Department of Hematology, University of FirenzeFirenze, Italy. ^[4] Department of Hematology and Oncology, Azienda Unità Sanitaria Locale di PiacenzaPiacenza, Italy. ^[5] Pathology, Azienda Ospedaliero Universitaria PisanaPisa, Italy. ^[6]

关键词 BCL2/IGH MRD PCR bendamustine follicular lymphoma rituximab

DOI 10.3389/fphar.2017.00413

PMID 28706485

发布时间 2023-11-04

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交